Short Term Trading Week Starting: 26 Apr, page-35

To be honest, I'm thinking that while $2 for MSB is tempting, it is best to stay away just because of the lack of short term catalysts. The only one that I can see still pending is the Novartis deal closing. Everything else seems to be more in the second half of the year. Happy to be wrong. Like you say - funds could be better utilised elsewhere. Thanks for your response!